This is desirable for those that would like the increase in blood testosterone levels without the added side effects that are present with androstendione. This substance was first listed in the WADA Prohibited List in 2004 as a steroid precursor. This substance was first referenced in the WADA Prohibited List in 2004 as a diagnostic metabolite for anabolic steroid use. This compound was first listed in the WADA Prohibited List in 2004 as a steroid precursor related to testosterone biosynthesis. This substance was identified in WADA documentation from 2004 as a diagnostic marker in urine for detection of anabolic steroid use. The detection of such substances in samples is labelled by WADA as an "adverse analytical finding" (AAF), which is distinct from "anti-doping rules violations" (ADRV). Glucocorticoids are a class of corticosteroids that affect the metabolism of carbohydrates, fat, and proteins, and regulate glycogen and blood pressure levels.
This substance (heroin) was first listed in the IOC doping list in 1988 as a narcotic analgesic. This substance was first listed in the IOC doping list on 31 January 1999 as a stimulant. This substance was first listed in the IOC doping list on 1 January 2003 as a stimulant (also known as MDMA). This substance was first listed in the IOC doping list in 1988 as a stimulant of the sympathomimetic amine class. This substance was first listed in the IOC doping list in 1988 as a stimulant.
The depot effect of an intramuscular testosterone ester preparation increases in proportion to the length of the ester side chain. The applied analytical method included liquid-liquid extraction and preparation of oxime derivatives, prior to TLX-sample clean-up and LC-MS/MS detection.In the clinical study, the elimination half-lives and detection times depended on the type of testosterone ester administrated. Three subjects were assigned to each study group and blood was collected throughout a testing period of 60 days.
This gene therapy product was first discussed in IOC/WADA contexts in 2003 as a form of genetic doping aimed at increasing erythropoietin expression. The steroid is used with a diet program to cause weight gain in people who have lost too much weight due to surgery, injury, chronic (long-lasting) infections, trauma, or who are underweight for unknown reasons. This metabolite was discussed in IOC anti-doping material from 2001 in relation to nandrolone detection. This metabolite of nandrolone was first identified in WADA lists and urinary threshold guidance from 2004.
Regardless, marijuana is prohibited in-competition by the World Anti-Doping Agency, and this status applies to all athletes regardless of the state laws where they live. Consumption of these products has resulted in numerous hospitalizations,  and the drugs have been reported to cause hallucinations, increased heartbeat and blood pressure, aggressive behavior, anxiety, muscle spasms, nausea, and vomiting. In conclusion, WADA maintains that cannabinoids belong on the WADA Prohibited List and the substance category will continue to be prohibited in-competition. A list of substances and methods currently being monitored by WADA for potential future inclusion on The Prohibited List. A directory of articles written by USADA, covering many substances and methods listed in The Prohibited List. The World Anti-Doping Agency (WADA) Prohibited List is the comprehensive document serving as the international standard for identifying substances and methods prohibited in sport. Therefore, athletes who plan on using a sustained-release preparation close to the in-competition period should keep all medical records in case a retroactive Therapeutic Use Exemption is required.